Immtech: Pafuramidine Trial Gets Fast-Track Status In China (China)
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration has granted Immtech Pharmaceuticals' application for fast-track status for conducting a Phase III clinical trial involving pafuramidine. Pafuramidine is the company's oral drug candidate for the treatment of Pneumocystis pneumonia, a fungal infection in the lungs that can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. (Click here for more - May Require Paid Subscription